Shawn K. Singh

Biography

Shawn is the CEO of VistaGen Therapeutics, a biotechnology company applying pluripotent stem cell technology for drug rescue and stem cell therapy. Mr. Singh joined the VistaGen Board of Directors in 2000 and its senior management team (part-time) in 2003 following their acquisition of Artemis Neuroscience, of which he was President. Mr. Singh has 20 years of experience working with public and private biotechnology and pharmaceutical companies. From February 2001 to August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer and General Counsel of Cato Research, a global CRO affiliated with Cato BioVentures. Mr. Singh also served as President (part-time) of Echo Therapeutics, Inc. (OTCBB: ECTE) from September 2007 to June 2009 and as CEO (part-time) of Hemodynamic Therapeutics, a majority-owned affiliate of Cato BioVentures, from November 2004 to August 2009. From late-2000 to February 2001, Mr. Singh served as Managing Director of Start-Up Law, a management consulting firm serving early-stage biotechnology companies. Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN) from late-1993 to late-2000 and as a corporate finance associate of Morrison & Foerster LLP, an international law firm from 1991 to late-1993. Mr. Singh also currently serves as a member of the Board of Directors of Echo Therapeutics (OTCBB: ECTE), Armour Therapeutics Inc, and Hemodynamic Therapeutics. Mr. Singh is a member of the State Bar of California. Shawn is the CEO of VistaGen Therapeutics, a biotechnology company applying pluripotent stem cell technology for drug rescue and stem cell therapy. Mr. Singh joined the VistaGen Board of Directors in 2000 and its senior management team (part-time) in 2003 following their acquisition of Artemis Neuroscience, of which he was President. Mr. Singh has 20 years of experience working with public and private biotechnology and pharmaceutical companies. From February 2001 to August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer and General Counsel of Cato Research, a global CRO affiliated with Cato BioVentures. Mr. Singh also served as President (part-time) of Echo Therapeutics, Inc. (OTCBB: ECTE) from September 2007 to June 2009 and as CEO (part-time) of Hemodynamic Therapeutics, a majority-owned affiliate of Cato BioVentures, from November 2004 to August 2009. From late-2000 to February 2001, Mr. Singh served as Managing Director of Start-Up Law, a management consulting firm serving early-stage biotechnology companies. Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN) from late-1993 to late-2000 and as a corporate finance associate of Morrison & Foerster LLP, an international law firm from 1991 to late-1993. Mr. Singh also currently serves as a member of the Board of Directors of Echo Therapeutics (OTCBB: ECTE), Armour Therapeutics Inc, and Hemodynamic Therapeutics. Mr. Singh is a member of the State Bar of California.

Research Interest

Biochemistry